Literature DB >> 23277761

Development and implementation of a computerized system for collection, processing, and administration of cellular therapy products.

Laura C Gatzos1, Susan Barbetti, Suzanne Bas-Davis, Albert Mailman, Philip Brzezinski, Paul Ruseau, Holly Barr Vermilya, Darlys Schott, Edna Marston, Olive J Sturtevant, Jerome Ritz, Lawrence N Shulman.   

Abstract

Great strides have been made in computerization of ordering processes for general medications and chemotherapy agents. However, systems for ordering, processing, and administration of cellular therapies continue to be largely paper-based, without the safety features of computerized order entry. To address this deficit, Partners Healthcare System Information Services (PHS-IS; Boston, MA) has worked with oncologists and staff in the cell processing laboratory at the Dana-Farber Cancer Institute (Boston, MA) to develop and implement a novel, comprehensive computerized system for physician ordering and management of cellular products. A multidisciplinary team was formed to accomplish the task of developing a cellular product management system. This team identified the unique characteristics of cellular therapies and sought to develop a comprehensive computerized system that addressed these needs. The biotherapy order entry system developed and implemented by PHS-IS includes a suite of three interrelated applications that addresses all requirements of a traditional computerized provider order entry system, as well as features unique to cellular therapies. The biotherapy suite of applications has addressed patient safety concerns, streamlined the ordering of cellular therapy products, and has reduced opportunities for error and delay in product administration.

Entities:  

Mesh:

Year:  2012        PMID: 23277761      PMCID: PMC3439224          DOI: 10.1200/JOP.2011.000499

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  19 in total

1.  Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Haesook T Kim; Julie Aldridge; Deborah Liney; Grace Kao; Philippe Armand; John Koreth; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-27       Impact factor: 5.742

2.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

3.  History of hematopoietic stem cell transplantation.

Authors:  Susan A Ezzone
Journal:  Semin Oncol Nurs       Date:  2009-05       Impact factor: 2.315

4.  Prostate cancer immunotherapy.

Authors:  Kenneth F May; James L Gulley; Charles G Drake; Glenn Dranoff; Philip W Kantoff
Journal:  Clin Cancer Res       Date:  2011-06-23       Impact factor: 12.531

5.  Comparison of cord blood thawing methods on cell recovery, potency, and infusion.

Authors:  Donna M Regan; Jonathan D Wofford; Donna A Wall
Journal:  Transfusion       Date:  2010-12       Impact factor: 3.157

Review 6.  Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease.

Authors:  Adam R Williams; Joshua M Hare
Journal:  Circ Res       Date:  2011-09-30       Impact factor: 17.367

7.  Integrated information systems for electronic chemotherapy medication administration.

Authors:  Mia A Levy; Dario A Giuse; Carol Eck; Gwen Holder; Giles Lippard; Julia Cartwright; Nancy K Rudge
Journal:  J Oncol Pract       Date:  2011-06-17       Impact factor: 3.840

8.  Medication safety in the ambulatory chemotherapy setting.

Authors:  Tejal K Gandhi; Sylvia B Bartel; Lawrence N Shulman; Deborah Verrier; Elisabeth Burdick; Angela Cleary; Jeffrey M Rothschild; Lucian L Leape; David W Bates
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

9.  PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

Authors:  Martin A Cheever; Celestia S Higano
Journal:  Clin Cancer Res       Date:  2011-04-06       Impact factor: 12.531

10.  Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.

Authors:  Vincent T Ho; Matthew Vanneman; Haesook Kim; Tetsuro Sasada; Yoon Joong Kang; Mildred Pasek; Corey Cutler; John Koreth; Edwin Alyea; Stefanie Sarantopoulos; Joseph H Antin; Jerome Ritz; Christine Canning; Jeffery Kutok; Martin C Mihm; Glenn Dranoff; Robert Soiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.